The US Bankruptcy Court gave an order approving the sale of certain assets of EPIRUS Biopharmaceuticals, Inc. on January 19, 2018. As per the order, trustee has been authorized to sell certain personal property to Praxis Precision Medicines, Inc. for $1.03 million. Cavion, Inc. has been designated as back-up bidder. The debtor’s assets include molecular compound known as Z944. At the auction held, Praxis Precision Medicines emerged as the winning bidder by offering a purchase price of $1.03 million whereas Cavion, Inc the stalking horse bidder, had offered a final purchase price of $0.5 million. Amoli Pandya is appointed as Attorney to the Praxis Precision Medicines.